GSA Capital Partners LLP Sells 342,584 Shares of ProKidney Corp. $PROK

GSA Capital Partners LLP decreased its holdings in ProKidney Corp. (NASDAQ:PROK) by 67.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 168,031 shares of the company’s stock after selling 342,584 shares during the quarter. GSA Capital Partners LLP’s holdings in ProKidney were worth $407,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd purchased a new position in shares of ProKidney during the 2nd quarter worth $208,000. Catalyst Funds Management Pty Ltd purchased a new stake in shares of ProKidney in the 2nd quarter worth $36,000. Zullo Investment Group Inc. bought a new position in ProKidney in the 3rd quarter worth $28,000. Bank of America Corp DE lifted its position in ProKidney by 12.4% during the second quarter. Bank of America Corp DE now owns 846,154 shares of the company’s stock valued at $501,000 after purchasing an additional 93,322 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in ProKidney during the second quarter valued at about $350,000. 51.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PROK. HC Wainwright initiated coverage on ProKidney in a research note on Tuesday, December 16th. They issued a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of ProKidney in a report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $7.40.

ProKidney Stock Up 0.9%

Shares of ProKidney stock opened at $2.26 on Thursday. The company has a market capitalization of $679.88 million, a price-to-earnings ratio of -4.11 and a beta of 1.78. The stock’s 50-day simple moving average is $2.19 and its 200-day simple moving average is $2.44. ProKidney Corp. has a 52 week low of $0.46 and a 52 week high of $7.13.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.